
- Oncology NEWS International Vol 16 No 11
- Volume 16
- Issue 11
Research funds pay off with mortality decline
The cancer death rate continues to decline, according to the latest report, and at an even faster rate than previously. Cancer mortality decreased by 2.1% per year from 2002 to 2004, almost double the 1.1% decline seen each year from 1993 to 2002.
The cancer death rate continues to decline, according to the latest report, and at an even faster rate than previously. Cancer mortality decreased by 2.1% per year from 2002 to 2004, almost double the 1.1% decline seen each year from 1993 to 2002.
The Annual Report to the Nation, produced by NCI, CDC, the American Cancer Society, and the North American Association of Central Cancer Registries, was published in Cancer (110:2119-2152, 2007), following advance online release.
The biggest contributor to the decline was the fall in colorectal cancer deaths in both men and women, the authors said. Such deaths dropped by 4.9% a year in men and 4.5% in women, due in part to advances in treatment, and new diagnoses of colorectal cancer were down 2.8% in men and 2.4% in women, probably due to colorectal screening.
ASCO president Nancy E. Davidson, MD, attributed the findings to the national investment in cancer research. "These exciting new data demonstrate what many of us in the cancer research and practice community have known for some time. The long-term federal investment in cancer research is paying off," she said, adding that "this impressive pace of progress will slow if we don't recommit to funding cancer research."
Articles in this issue
almost 18 years ago
MT103, BiTE antibody, enters phase II testing for ALLalmost 18 years ago
Sides dig in as ESA policy debate heats upalmost 18 years ago
Ixempra gets ok for resistant breast canceralmost 18 years ago
ASCO adds Oncotype DX to marker guidelinealmost 18 years ago
Dr. Norton hopes to weed 'molecular' tumor gardenalmost 18 years ago
Accelerated approval for Tasignaalmost 18 years ago
Oxidative stress inducer ups survival in advanced melanomaalmost 18 years ago
FDA removes partial hold on Telcyta clinical developmentalmost 18 years ago
Should all HER2+ pts receive adjuvant trastuzumab?almost 18 years ago
R-CHOP is standard of care for advanced DLBCL patientsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.